Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Adagene Begins Phase 2 Neoadjuvant Muzastotug in CRC
Details : ADG126 (muzastotug) is a fully human anti-CTLA-4 SAFEbody. It is under development for metastatic microsatellite-stable colorectal cancer.
Product Name : ADG126
Product Type : Antibody
Upfront Cash : Inapplicable
February 27, 2025
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Adagene to Present Muzastotug + KEYTRUDA® Data at ASCO GI Symposium
Details : ADG126 (muzastotug) is a fully human anti-CTLA-4 SAFEbody. It is under development for metastatic microsatellite-stable colorectal cancer.
Product Name : ADG126
Product Type : Antibody
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer
Details :
Product Name : AMP945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : AMP945,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Adagene Expands Collaboration Program for ADG126 with KEYTRUDA® Efficacy
Details :
Product Name : ADG126
Product Type : Antibody
Upfront Cash : Inapplicable
September 02, 2024
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Fluorouracil
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Clearance of Amplia's IND for Pancreatic Cancer Trial in US
Details :
Product Name : AMP945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 17, 2024
Lead Product(s) : AMP945,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adagene Presents Data on ADG126 Combined with Pembrolizumab in MSS Colorectal Cancer
Details :
Product Name : ADG126
Product Type : Antibody
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : ADG126
Product Type : Antibody
Upfront Cash : Inapplicable
September 01, 2023
Lead Product(s) : AMP945,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945,Fluorouracil
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in Model of Pancreatic Cancer
Details :
Product Name : AMP945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 29, 2023
Lead Product(s) : AMP945,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AMP945
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : CSIRO
Deal Size : Undisclosed
Deal Type : Collaboration
Amplia Receives Grant to Collaborate with CSIRO – Supplementary Announcement
Details :
Product Name : AMP945
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 23, 2023
Lead Product(s) : AMP945
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : CSIRO
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : AMP945,Toripalimab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Exelixis
Deal Size : Undisclosed
Deal Type : Collaboration
Details :
Product Name : ADG126
Product Type : Antibody
Upfront Cash : $12.1 million
April 05, 2023
Lead Product(s) : AMP945,Toripalimab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Exelixis
Deal Size : Undisclosed
Deal Type : Collaboration